Patents by Inventor Kiyotoshi Sekiguchi
Kiyotoshi Sekiguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190049429Abstract: A method for observing the dynamics of sweat glands and a method for evaluating a substance of interest, which are useful for development of a preparation for external application, such as a cosmetic. In each of the methods, an observation sample is used, which is prepared by staining all sweat glands, which are isolated alive, with a staining reagent, and then holding the all sweat glands on a support using at least one material selected from the group consisting of collagen, agarose, basement membrane matrix, poly-D-lysine and a membrane.Type: ApplicationFiled: July 18, 2017Publication date: February 14, 2019Applicants: MANDOM CORPORATION, OSAKA UNIVERSITYInventors: Kie Nakashima, Ryuichiro Kurata, Fumitaka Fujita, Kiyotoshi Sekiguchi, Atsushi Tanemura, Hiroyuki Murota, Ichiro Katayama
-
Publication number: 20180208893Abstract: Provided is a method for producing vascular endothelial cells from pluripotent stem cells, the method comprising the following steps (i) to (iii): (i) a step of culturing pluripotent stem cells in a culture medium comprising a BMP, on a culture vessel coated with a first matrix, to produce mesodermal progenitor cells; (ii) a step of dissociating the resulting cells into single cells; and (iii) a step of culturing the resulting cells in a culture medium comprising VEGF, on a culture vessel coated with a second matrix selected from the group consisting of laminin-411 or a fragment thereof, laminin-511 or a fragment thereof, Matrigel, type IV collagen and fibronectin.Type: ApplicationFiled: July 14, 2016Publication date: July 26, 2018Inventors: Tatsutoshi Nakahata, Megumu Saito, Akira Niwa, Ryo Ota, Kiyotoshi Sekiguchi
-
Patent number: 10000554Abstract: A modified laminin characterized in that a laminin or a heterotrimeric laminin fragment has a collagen binding molecule conjugated to at least one site selected from the ? chain N-terminus, the ? chain N-terminus and the ? chain N-terminus, and an extracellular-matrix material comprising the modified laminin, and collagen and/or gelatin serve as an alternative to Matrigel and are useful as an extracellular-matrix material for the formation of a safe three-dimensional tissue structure for regenerative medicine in humans.Type: GrantFiled: November 11, 2013Date of Patent: June 19, 2018Assignee: OSAKA UNIVERSITYInventors: Kiyotoshi Sekiguchi, Shaoliang Li, Ryoko Sato
-
Patent number: 9758765Abstract: Provided are a modified laminin having a cell-growth regulatory molecule bound to at least one site selected from the ? chain N-terminus, the ? chain C-terminus, the ? chain N-terminus and the ? chain N-terminus of laminin or a heterotrimeric laminin fragment, a method for culturing cells in the presence of the modified laminin, a method for establishing iPS cells in the presence of the modified laminin, and a culture substrate coated with the modified laminin. Human stem cells cultured in a xeno-free environment with the use of the modified laminin of the present invention can be provided as highly safe human stem cells applicable to regenerative medicine.Type: GrantFiled: April 9, 2012Date of Patent: September 12, 2017Assignees: OSAKA UNIVERSITY, KYOTO UNIVERSITYInventors: Kiyotoshi Sekiguchi, Yukimasa Taniguchi, Masato Nakagawa
-
Publication number: 20170159020Abstract: The present invention provides a novel technique in a cell culture method using a cell culture vessel coated with a laminin fragment, which novel technique achieves cell culture as in the case of using a recommended coating concentration even when the coating concentration is lower than the recommended coating concentration. The present invention relates to a method for enhancing an activity for mammalian cultured cells of a laminin fragment or a variant thereof each having integrin binding activity.Type: ApplicationFiled: July 15, 2015Publication date: June 8, 2017Applicant: OSAKA UNIVERSITYInventors: Kiyotoshi SEKIGUCHI, Ko TSUTSUI
-
Publication number: 20160244721Abstract: The present invention provides a method of purifying highly pure retinal pigment epithelial cells from a cell population obtained by induction of differentiation of pluripotent stem cells into retinal pigment epithelial cells, by a simple and easy operation in a short period. The purification method of the present invention includes a step of introducing a cell population containing retinal pigment epithelial cells obtained by differentiation induction of pluripotent stem cells on laminin or a fragment thereof on a filter, and obtaining a cell population that passed the filter.Type: ApplicationFiled: October 9, 2014Publication date: August 25, 2016Applicants: HEALIOS K.K., OSAKA UNIVERSITYInventors: Masanori SAWADA, Kiyotoshi SEKIGUCHI
-
Publication number: 20160237403Abstract: Provided are a production method of retinal pigment epithelial (RPE) cells that improves differentiation induction efficiency of pluripotent stem cells into RPE cells, and can provide highly pure RPE cells by a simple and easy operation in a short period, a culture method of RPE cells that can stably grow and culture a cell, a toxicity/efficacy evaluation method using RPE cells useful for transplantation therapy, and a therapeutic drug for a retinal disease. The invention relates to a production method of RPE cells, comprising adhesion culture of human pluripotent stem cells using a culture substrate coated with a laminin-E8 fragment, a culture method of RPE cells, comprising adhesion culture of RPE cells using a culture substrate coated with a laminin-E8 fragment, a toxicity or efficacy evaluation method using RPE cells obtained by producing or culturing by the method, and a therapeutic drug for a retinal disease, containing the RPE cells.Type: ApplicationFiled: October 9, 2014Publication date: August 18, 2016Applicants: HEALIOS K.K., RIKEN, OSAKA UNIVERSITYInventors: Masanori SAWADA, Masayo TAKAHASHI, Kiyotoshi SEKIGUCHI
-
Publication number: 20160215260Abstract: The present invention provides a method for producing dopaminergic neuron progenitor cells from pluripotent stem cells, which method comprises the steps of: (i) performing adherent culture of pluripotent stem cells on an extracellular matrix in a medium containing a reagent(s) selected from the group consisting of BMP inhibitor, TGF? inhibitor, SHH signal-stimulating agent, FGF8, and GSK3? inhibitor; (ii) collecting Corin- and/or Lrtm1-positive cells from the cells obtained in Step (i) using a substance which binds to Corin and/or a substance which binds to Lrtm1; and (iii) performing suspension culture of the cells obtained in Step (ii) in a medium containing a neurotrophic factor.Type: ApplicationFiled: September 4, 2014Publication date: July 28, 2016Inventors: Jun Takahashi, Daisuke Doi, Bumpei Samata, Kiyotoshi Sekiguchi, Yuichi Ono
-
Publication number: 20160137965Abstract: Provided is a cell culture vessel characterized in that a surface to be in contact with cells is coated with a laminin fragment having integrin ?6?1 binding activity or a modified form thereof in a dry state, the laminin fragment being derived from at least one kind selected from laminin ?5?1?1 and laminin ?5?2?1, the cell culture vessel being any of the following: (1) a cell culture vessel of which a surface to be in contact with cells is coated only with a laminin fragment having integrin ?6?1 binding activity or a modified form thereof in a dry state; (2) a cell culture vessel of which a surface to be in contact with cells is coated with a laminin fragment having integrin ?6?1 binding activity or a modified form thereof in combination with a laminin fragment having no integrin ?6?1 binding activity in a dry state; and (3) a cell culture vessel of which a surface to be in contact with cells is coated with a laminin fragment having integrin ?6?1 binding activity or a modified form thereof in combinationType: ApplicationFiled: May 9, 2014Publication date: May 19, 2016Applicant: OSAKA UNIVERSITYInventors: Kiyotoshi SEKIGUCHI, Ko TSUTSUI
-
Publication number: 20160052994Abstract: A modified laminin characterized in that a laminin or a heterotrimeric laminin fragment has a collagen binding molecule conjugated to at least one site selected from the ? chain N-terminus, the ? chain N-terminus and the ? chain N-terminus, and an extracellular-matrix material comprising the modified laminin, and collagen and/or gelatin serve as an alternative to Matrigel and are useful as an extracellular-matrix material for the formation of a safe three-dimensional tissue structure for regenerative medicine in humans.Type: ApplicationFiled: November 11, 2013Publication date: February 25, 2016Inventors: Kiyotoshi SEKIGUCHI, Shaoliang LI, Ryoko SATO
-
Publication number: 20160046904Abstract: Provided is a method of stably maintaining and culturing “hepatoblast-like cells” generated during a differentiation-inducing process from pluripotent stem cells to hepatocytes. The present invention also provides a culture product obtained by the culture method. The hepatoblast-like cells can be maintained and cultured stably by bringing a laminin into contact with the hepatoblast-like cells. The method of the present invention which uses a laminin makes it possible for the first time to culture, maintain, and proliferate the hepatoblast-like cells. Desired mature cells such as mature hepatocytes and bile duct epithelial cells can be generated in a short time period and can be acquired at a desired timing by maintaining the hepatoblast-like cells. Further, the resulting cultured hepatoblast-like cells were demonstrated to be capable of being induced to differentiate into mature hepatocytes, mature cholangiocytes, bile duct epithelial cells, and the like.Type: ApplicationFiled: April 8, 2014Publication date: February 18, 2016Inventors: Hiroyuki MIZUGUCHI, Kenji KAWABATA, Kazuo TAKAYAMA, Kiyotoshi SEKIGUCHI
-
Publication number: 20150086557Abstract: Provided is a novel ligand for integrin ?9?1 consisting of a peptide having the following amino acid sequence: (A) EDDMMEVPY (SEQ ID NO: 1) or (B) an amino acid sequence the same as the amino acid sequence represented by SEQ ID NO: 1 except for having deletion, substitution or addition of 1 to 3 amino acids. The novel ligand for integrin ?9?1 has a higher binding affinity than those of tenascin-C and osteodontin, which are known ligands for integrin ?9?1.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Inventors: Kiyotoshi Sekiguchi, Ryoko Sato, Sachiko Ezoe
-
Patent number: 8877493Abstract: The present invention provides a culture substrate which enables maintenance culture of human pluripotent stem cells in a pluripotent state under a feeder-free culture environment, and a culture method of human pluripotent stem cells using the culture substrate. By seeding human pluripotent stem cells dissociated into single cells at a cell density of 4×104 to 10×104 cells/cm2 onto a culture substrate coated with human laminin ?5?1?1 E8 fragment or human laminin ?3?3?2 E8 fragment preferably at a concentration of 0.5 to 25 ?g/cm2, the human pluripotent stem cells can be rapidly expanded in a pluripotent state.Type: GrantFiled: October 7, 2010Date of Patent: November 4, 2014Assignees: Osaka University, Kyoto UniversityInventors: Kiyotoshi Sekiguchi, Sugiko Futaki, Yukimasa Taniguchi, Maria Hayashi, Norio Nakatsuji, Takamichi Miyazaki, Eihachiro Kawase, Hirofumi Suemori
-
Publication number: 20140127806Abstract: Provided are a modified laminin having a cell-growth regulatory molecule bound to at least one site selected from the ? chain N-terminus, the ? chain C-terminus, the ? chain N-terminus and the ? chain N-terminus of laminin or a heterotrimeric laminin fragment, a method for culturing cells in the presence of the modified laminin, a method for establishing iPS cells in the presence of the modified laminin, and a culture substrate coated with the modified laminin. Human stem cells cultured in a xeno-free environment with the use of the modified laminin of the present invention can be provided as highly safe human stem cells applicable to regenerative medicine.Type: ApplicationFiled: April 9, 2012Publication date: May 8, 2014Applicants: KYOTO UNIVERSITY, OSAKA UNIVERSITYInventors: Kiyotoshi Sekiguchi, Yukimasa Taniguchi, Masato Nakagawa
-
Patent number: 8691951Abstract: It is an object of the present invention to provide a Type I-Type IV collagen hybrid gel, which maintains characteristics of a Type IV collagen and is superior in gel strength. It is the Type I-Type IV collagen hybrid gel obtained by mixing 100 to 500 parts by mass of the Type I collagen having fibrosis ability, relative to 100 parts by mass of the Type IV collagen having gelling ability. A three-dimensional structure is formed, where a membrane-like substance by the Type IV collagen is formed onto a fibrous substance by the Type I collagen, so as to be able to provide cell culture environment approximate to a basement membrane of a living body.Type: GrantFiled: February 14, 2011Date of Patent: April 8, 2014Assignees: Japan Institute of Leather Research, Osaka UniversityInventors: Shunji Hattori, Yoh-ichi Koyama, Hitomi Fujisaki, Kiyotoshi Sekiguchi, Sugiko Futaki, Ryoko Sato
-
Publication number: 20120220031Abstract: The present invention provides a culture substrate which enables maintenance culture of human pluripotent stem cells in a pluripotent state under a feeder-free culture environment, and a culture method of human pluripotent stem cells using the culture substrate. By seeding human pluripotent stem cells dissociated into single cells at a cell density of 4×104 to 10×104 cells/cm2 onto a culture substrate coated with human laminin ?5?1?1 E8 fragment or human laminin ?3?3?2 E8 fragment preferably at a concentration of 0.5 to 25 ?g/cm2, the human pluripotent stem cells can be rapidly expanded in a pluripotent state.Type: ApplicationFiled: October 7, 2010Publication date: August 30, 2012Inventors: Kiyotoshi Sekiguchi, Sugiko Futaki, Yukimasa Taniguchi, Maria Hayashi, Norio Nakatsuji, Takamichi Miyazaki, Eihachiro Kawase, Hirofumi Suemori
-
Publication number: 20120208761Abstract: It is an object of the present invention to provide a Type I-Type IV collagen hybrid gel, which maintains characteristics of a Type IV collagen and is superior in gel strength. It is the Type I-Type IV collagen hybrid gel obtained by mixing 100 to 500 parts by mass of the Type I collagen having fibrosis ability, relative to 100 parts by mass of the Type IV collagen having gelling ability. A three-dimensional structure is formed, where a membrane-like substance by the Type IV collagen is formed onto a fibrous substance by the Type I collagen, so as to be able to provide cell culture environment approximate to a basement membrane of a living body.Type: ApplicationFiled: February 14, 2011Publication date: August 16, 2012Inventors: Shunji Hattori, Yoh-ichi Koyama, Hitomi Fujisaki, Kiyotoshi Sekiguchi, Sugiko Futaki, Ryoko Sato
-
Publication number: 20070269835Abstract: A method of determining a laminin 5 antigen in a biological sample, comprising the steps of bringing an antibody reactive to a laminin 5 ?2 chain N-terminal fragment into contact with the biological sample; measuring a reaction of the antibody; and determining an amount of the laminin 5 antigen based on a measurement result of the reaction, as well as, a method of detecting a laminin 5-producing tumor cell, a method of examining acute respiratory distress syndrome and a method of evaluating malignancy of a malignant tumor based on the assay method.Type: ApplicationFiled: July 3, 2007Publication date: November 22, 2007Inventors: Masahiko Katayama, Noriko Sanzen, Kiyotoshi Sekiguchi
-
Patent number: 7256001Abstract: A method of determining a laminin 5 antigen in a biological sample, comprising the steps of bringing an antibody reactive to a laminin 5 ?2 chain N-terminal fragment into contact with the biological sample; measuring a reaction of the antibody; and determining an amount of the laminin 5 antigen based on a measurement result of the reaction, as well as, a method of detecting a laminin 5-producing tumor cell, a method of examining acute respiratory distress syndrome and a method of evaluating malignancy of a malignant tumor based on the assay method.Type: GrantFiled: August 19, 2002Date of Patent: August 14, 2007Assignee: Eisai R&D Management Co., Ltd.Inventors: Masahiko Katayama, Noriko Sanzen, Kiyotoshi Sekiguchi
-
Publication number: 20040265937Abstract: A method of determining a laminin 5 antigen in a biological sample, comprising the steps of bringing an antibody reactive to a laminin 5 &ggr;2 chain N-terminal fragment into contact with the biological sample; measuring a reaction of the antibody; and determining an amount of the laminin 5 antigen based on a measurement result of the reaction, as well as, a method of detecting a laminin 5-producing tumor cell, a method of examining acute respiratory distress syndrome and a method of evaluating malignancy of a malignant tumor based on the assay method.Type: ApplicationFiled: February 17, 2004Publication date: December 30, 2004Inventors: Masahiko Katayama, Noriko Sanzen, Kiyotoshi Sekiguchi